Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
5 Life Science Trends To Watch
During the pandemic, clinical trials were impacted as people avoided unnecessary interactions with healthcare. As the nation continues to adjust, here are five trends that will change the way medical solutions are developed and administered.
A Nigerian Student’s Striking Pictures Illustrate Lessons We All Must Learn
Academia and industry must transform how we see skin — and how the medical field represents diverse identities.
How We Collaborated With The FDA For Clinical Trial Success
To overcome the unique challenges associated with conducting rare disease clinical trials, Timber Pharmaceuticals began formal discussions with the FDA early on.
3 Essential Leadership Values for Today’s Evolved Workforce
There have been three qualities that, as a leader, have served me well throughout my career. Often described as “soft skills,” there is nothing soft about them. They are foundational.
Precision Medicine And Understanding Value In Healthcare
With the advent of precision medicine comes an increased focus on the idea of value-based care. But how do we define value?
Early On, Biotechs Need To Be Thinking Commercialization
Does commercialization strategy matter when you are years from having a commercial product? In my experience in biotech, the answer is a resounding yes.
The Trojan Horse Of Small Talk
Amy Mahery of EMD Serono talks about how to deal with our hidden biases and assumptions related to diversity, equity, and inclusion.
The Challenges — And Opportunities — Facing The European Biotech Industry
Converting cutting-edge research into viable products remains a challenge for the European biotech sector. Jonathan Hay of Delin Ventures investigates how ambition can translate to reality.
I’ve Learned That Hope Is At The Center Of Innovation
In biotech, results show that every innovative success must subsidize nine expensive failures. Fundamentally, this is an industry of optimists, and we do not give up against overwhelming odds.
Building Scientific Trust Virtually
How do you build, manage, and grow global oncology teams in opposite time zones amidst a pandemic? It’s a question I asked myself as I accepted a new position eight months into the COVID-19 lockdown.
BEYOND THE PRINTED PAGE
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
LIFE SCIENCE LEADER BLOGS
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.